Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1998 Dec;78(11):1479–1487. doi: 10.1038/bjc.1998.710

Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group.

K Aabo, M Adams, P Adnitt, D S Alberts, A Athanazziou, V Barley, D R Bell, U Bianchi, G Bolis, M F Brady, H S Brodovsky, H Bruckner, M Buyse, R Canetta, V Chylak, C J Cohen, N Colombo, P F Conte, D Crowther, J H Edmonson, C Gennatas, E Gilbey, M Gore, D Guthrie, B Y Yeap, et al.
PMCID: PMC2063202  PMID: 9836481

Abstract

The purpose of this systematic study was to provide an up to date and reliable quantitative summary of the relative benefits of various types of chemotherapy (non-platinum vs platinum, single-agent vs combination and carboplatin vs cisplatin) in the treatment of advanced ovarian cancer. Also, to investigate whether well-defined patient subgroups benefit more or less from cisplatin- or carboplatin-based therapy. Meta-analyses were based on updated individual patient data from all available randomized controlled trials (published and unpublished), including 37 trials, 5667 patients and 4664 deaths. The results suggest that platinum-based chemotherapy is better than non-platinum therapy, show a trend in favour of platinum combinations over single-agent platinum, and suggest that cisplatin and carboplatin are equally effective. There is no good evidence that cisplatin is more or less effective than carboplatin in any particular subgroup of patients.

Full text

PDF
1479

Images in this article

1481Figure 1
on p.1481
1482Figure 2
on p.1482
1483Figure 3
on p.1483

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adams M., Kerby I. J., Rocker I., Evans A., Johansen K., Franks C. R. A comparison of the toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer. The Swons Gynaecological Cancer Group. Acta Oncol. 1989;28(1):57–60. doi: 10.3109/02841868909111182. [DOI] [PubMed] [Google Scholar]
  2. Alberts D. S., Green S., Hannigan E. V., O'Toole R., Stock-Novack D., Anderson P., Surwit E. A., Malvlya V. K., Nahhas W. A., Jolles C. J. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol. 1992 May;10(5):706–717. doi: 10.1200/JCO.1992.10.5.706. [DOI] [PubMed] [Google Scholar]
  3. Anderson H., Wagstaff J., Crowther D., Swindell R., Lind M. J., McGregor J., Timms M. S., Brown D., Palmer P. Comparative toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer. Eur J Cancer Clin Oncol. 1988 Sep;24(9):1471–1479. doi: 10.1016/0277-5379(88)90338-0. [DOI] [PubMed] [Google Scholar]
  4. Bajorin D. F., Sarosdy M. F., Pfister D. G., Mazumdar M., Motzer R. J., Scher H. I., Geller N. L., Fair W. R., Herr H., Sogani P. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol. 1993 Apr;11(4):598–606. doi: 10.1200/JCO.1993.11.4.598. [DOI] [PubMed] [Google Scholar]
  5. Bell D. R., Woods R. L., Levi J. A., Fox R. M., Tattersall M. H. Advanced ovarian cancer: a prospective randomised trial of chlorambucil versus combined cyclophosphamide and cis-diamminedichloroplatinum. Aust N Z J Med. 1982 Jun;12(3):245–249. doi: 10.1111/j.1445-5994.1982.tb02469.x. [DOI] [PubMed] [Google Scholar]
  6. Carmo-Pereira J., Costa F. O., Henriques E. cis-Platinum, adriamycin, and hexamethylmelamine versus cyclophosphamide in advanced ovarian carcinoma. Cancer Chemother Pharmacol. 1983;10(2):100–103. doi: 10.1007/BF00446218. [DOI] [PubMed] [Google Scholar]
  7. Chalmers I., Haynes B. Reporting, updating, and correcting systematic reviews of the effects of health care. BMJ. 1994 Oct 1;309(6958):862–865. doi: 10.1136/bmj.309.6958.862. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Cohen C. J., Goldberg J. D., Holland J. F., Bruckner H. W., Deppe G., Gusberg S. B., Wallach R. C., Kabakow B., Rodin J. Improved therapy with cisplatin regimens for patients with ovarian carcinoma (FIGO Stages III and IV) as measured by surgical end-staging (second-look operation). Am J Obstet Gynecol. 1983 Apr 15;145(8):955–967. doi: 10.1016/0002-9378(83)90849-9. [DOI] [PubMed] [Google Scholar]
  9. Conte P. F., Bruzzone M., Carnino F., Chiara S., Donadio M., Facchini V., Fioretti P., Foglia G., Gadducci A., Gallo L. Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide: a randomized trial in stage III-IV epithelial ovarian carcinoma. J Clin Oncol. 1991 Apr;9(4):658–663. doi: 10.1200/JCO.1991.9.4.658. [DOI] [PubMed] [Google Scholar]
  10. Edmonson J. H., McCormack G. M., Wieand H. S., Kugler J. W., Krook J. E., Stanhope C. R., Everson L. K., Laurie J. A., Ebbert L. P., Malkasian G. D. Cyclophosphamide-cisplatin versus cyclophosphamide-carboplatin in stage III-IV ovarian carcinoma: a comparison of equally myelosuppressive regimens. J Natl Cancer Inst. 1989 Oct 4;81(19):1500–1504. doi: 10.1093/jnci/81.19.1500. [DOI] [PubMed] [Google Scholar]
  11. Freedman L. S. Tables of the number of patients required in clinical trials using the logrank test. Stat Med. 1982 Apr-Jun;1(2):121–129. doi: 10.1002/sim.4780010204. [DOI] [PubMed] [Google Scholar]
  12. Kato T., Nishimura H., Yamabe T., Terashima Y., Kasamatsu T., Hirabayashi K., Nishiya I., Yajima A., Takamizawa H., Tsutsui F. [Phase III study of carboplatin in ovarian cancer]. Gan To Kagaku Ryoho. 1988 Aug;15(8):2297–2304. [PubMed] [Google Scholar]
  13. Leonard R. C., Smart G. E., Livingstone J. R., Cornbleet M. A., Kerr G. R., Fletcher S., Webb J. N., Smyth J. F. Randomised trial comparing prednimustine with combination chemotherapy in advanced ovarian carcinoma. Cancer Chemother Pharmacol. 1989;23(2):105–110. doi: 10.1007/BF00273526. [DOI] [PubMed] [Google Scholar]
  14. Masding J., Sarkar T. K., White W. F., Barley V. L., Chawla S. L., Boesen E., Rostom A. Y., Menday A. P. Intravenous treosulfan versus intravenous treosulfan plus cisplatinum in advanced ovarian carcinoma. Br J Obstet Gynaecol. 1990 Apr;97(4):342–351. doi: 10.1111/j.1471-0528.1990.tb01813.x. [DOI] [PubMed] [Google Scholar]
  15. Omura G., Blessing J. A., Ehrlich C. E., Miller A., Yordan E., Creasman W. T., Homesley H. D. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study. Cancer. 1986 May 1;57(9):1725–1730. doi: 10.1002/1097-0142(19860501)57:9<1725::aid-cncr2820570903>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  16. Rankin E. M., Mill L., Kaye S. B., Atkinson R., Cassidy L., Cordiner J., Cruickshank D., Davis J., Duncan I. D., Fullerton W. A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer. Br J Cancer. 1992 Feb;65(2):275–281. doi: 10.1038/bjc.1992.55. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Skarlos D. V., Aravantinos G., Kosmidis P., Pavlidis N., Gennatas K., Beer M., Mylonakis N., Makrantonakis P., Klouvas G., Karpathios S. Carboplatin alone compared with its combination with epirubicin and cyclophosphamide in untreated advanced epithelial ovarian cancer: a Hellenic co-operative oncology group study. Eur J Cancer. 1996 Mar;32A(3):421–428. doi: 10.1016/0959-8049(95)00537-4. [DOI] [PubMed] [Google Scholar]
  18. Swenerton K., Jeffrey J., Stuart G., Roy M., Krepart G., Carmichael J., Drouin P., Stanimir R., O'Connell G., MacLean G. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1992 May;10(5):718–726. doi: 10.1200/JCO.1992.10.5.718. [DOI] [PubMed] [Google Scholar]
  19. Taylor A. E., Wiltshaw E., Gore M. E., Fryatt I., Fisher C. Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer. J Clin Oncol. 1994 Oct;12(10):2066–2070. doi: 10.1200/JCO.1994.12.10.2066. [DOI] [PubMed] [Google Scholar]
  20. Tomirotti M., Perrone S., Giè P., Canaletti R., Carpi A., Biasoli R., Lombardi F., Giovanninetti A., Mensi F., Villa S. Cisplatin (P) versus cyclophosphamide, adriamycin and cisplatin (CAP) for stage III-IV epithelial ovarian carcinoma: a prospective randomized trial. Tumori. 1988 Oct 31;74(5):573–577. doi: 10.1177/030089168807400514. [DOI] [PubMed] [Google Scholar]
  21. Wadler S., Yeap B., Vogl S., Carbone P. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878. Cancer. 1996 Feb 15;77(4):733–742. [PubMed] [Google Scholar]
  22. Wilbur D. W., Rentschler R. E., Wagner R. J., Keeney E. D., King A., Hilliard D. A. Randomized trial of the addition of cis-platin (DDP) and/or BCG to cyclophosphamide (CTX) chemotherapy for ovarian carcinoma. J Surg Oncol. 1987 Mar;34(3):165–169. doi: 10.1002/jso.2930340306. [DOI] [PubMed] [Google Scholar]
  23. Williams C. J., Mead G. M., Macbeth F. R., Thompson J., Whitehouse J. M., MacDonald H., Harvey V. J., Slevin M. L., Lister T. A., Shepherd J. H. Cisplatin combination chemotherapy versus chlorambucil in advanced ovarian carcinoma: mature results of a randomized trial. J Clin Oncol. 1985 Nov;3(11):1455–1462. doi: 10.1200/JCO.1985.3.11.1455. [DOI] [PubMed] [Google Scholar]
  24. Wiltshaw E., Evans B., Rustin G., Gilbey E., Baker J., Barker G. A prospective randomized trial comparing high-dose cisplatin with low-dose cisplatin and chlorambucil in advanced ovarian carcinoma. J Clin Oncol. 1986 May;4(5):722–729. doi: 10.1200/JCO.1986.4.5.722. [DOI] [PubMed] [Google Scholar]
  25. Yusuf S., Peto R., Lewis J., Collins R., Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335–371. doi: 10.1016/s0033-0620(85)80003-7. [DOI] [PubMed] [Google Scholar]
  26. de Oliveira C. F., Lacave A. J., Villani C., Wolff J. P., di Re F., Namer M., Maskens A., George M., Dalesio O., Rotmensz N. Randomized comparison of cyclophosphamide, doxorubicin and cisplatin (CAP) versus cyclophosphamide and doxorubicin (CA) for the treatment of advanced ovarian cancer (ADOVCA). A EORTC Gynecological Cancer Cooperative Group Study. Eur J Gynaecol Oncol. 1990;11(5):323–330. [PubMed] [Google Scholar]
  27. ten Bokkel Huinink W. W., van der Burg M. E., van Oosterom A. T., Neijt J. P., George M., Guastalla J. P., Veenhof C. H., Rotmensz N., Dalesio O., Vermorken J. B. Carboplatin in combination therapy for ovarian cancer. Cancer Treat Rev. 1988 Jun;15 (Suppl B):9–15. doi: 10.1016/0305-7372(88)90030-8. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES